Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Andy Schuetz"'
Publikováno v:
In Clinical Therapeutics 1 January 2014 36(1):58-69
Autor:
C Andy Schuetz, Peter Alperin, Swathi Guda, Andrew van Herick, Bertrand Cariou, David Eddy, Janusz Gumprecht, Antonio Nicolucci, Peter Schwarz, Nick J Wareham, Daniel R Witte, Ulf Smith
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e66454 (2013)
No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease. We used a mathematical model to estimate the cost-effectiveness of several health check strategies in six European co
Externí odkaz:
https://doaj.org/article/6e9c40b78e7b4396826279692a605a5c
Publikováno v:
Journal of the American Medical Informatics Association : JAMIA
Objective: We explored whether use of deep learning to model temporal relations among events in electronic health records (EHRs) would improve model performance in predicting initial diagnosis of heart failure (HF) compared to conventional methods th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1f66fd4abc07c82a80aa4ad9886e184
https://doi.org/10.1093/jamia/ocw112
https://doi.org/10.1093/jamia/ocw112
Publikováno v:
JMLR workshop and conference proceedings. 56
Leveraging large historical data in electronic health record (EHR), we developed Doctor AI, a generic predictive model that covers observed medical conditions and medication uses. Doctor AI is a temporal model using recurrent neural networks (RNN) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1af3b27603815843fc51757f78769611
https://pubmed.ncbi.nlm.nih.gov/28286600
https://pubmed.ncbi.nlm.nih.gov/28286600
Publikováno v:
Clinical Therapeutics. 36:58-69
Background Now that generic atorvastatin has become available, a process of switching from rosuvastatin to atorvastatin may occur and could persist until the patent on branded rosuvastatin expires. It is important to understand the impact that such t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bc2d016ff3026b19a2afe2585770d36
https://doi.org/10.1016/j.clinthera.2013.12.003
https://doi.org/10.1016/j.clinthera.2013.12.003
Publikováno v:
Journal of Medical Economics. 15:1118-1129
This study used simulation to compare the effectiveness of rosuvastatin 20 mg vs atorvastatin 40 mg, and rosuvastatin 40 mg vs atorvastatin 80 mg in preventing MACE in a range of patient populations with varying baseline cardiovascular risk.The Archi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99d2aef0e56d389e5cd28e4f5207f086
https://doi.org/10.3111/13696998.2012.704459
https://doi.org/10.3111/13696998.2012.704459
Autor:
Bertrand Cariou, Daniel R. Witte, Swathi Guda, Antonio Nicolucci, Peter Alperin, Andy Schuetz, Nicholas J. Wareham, Andrew van Herick, Peter Schwarz, Janusz Gumprecht, Ulf Smith, David M. Eddy
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e66454 (2013)
PLoS ONE
PLoS ONE
Background No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease. We used a mathematical model to estimate the cost-effectiveness of several health check strategies in six
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cd0c036e9ca42e366864b54e95991e2
http://europepmc.org/articles/PMC3712021?pdf=render
http://europepmc.org/articles/PMC3712021?pdf=render
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 5
Objective: Using simulation modeling, we compared the effects of initiating statin therapy with atorvastatin and rosuvastatin on a population of patients with LDL-C levels above goal. Methods: Using the Archimedes Model, a clinically detailed simulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0033cf907880c58e0e58a47610400be
https://doi.org/10.1161/circoutcomes.5.suppl_1.a243
https://doi.org/10.1161/circoutcomes.5.suppl_1.a243
Autor:
Benjamin I. Rosner, Rebecca S. Lipner, Weifeng Weng, Barbara Peskin, Bradley M. Gray, C. Andy Schuetz
Publikováno v:
Health affairs (Project Hope). 31(1)
Managing diabetes and preventing its associated morbidities require active partnerships between physicians and patients. Studies to date lack the level of detail to quantify the degree to which interventions that are more controlled by physicians inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f4e880ff79b70d0cf8fb9be0c09788e
https://pubmed.ncbi.nlm.nih.gov/22232104
https://pubmed.ncbi.nlm.nih.gov/22232104
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Charles Andy Schuetz,1 Siew Hwa Ong,2 Matthias Blüher3 1Evidera Inc., Bethesda, MD, USA; 2Novartis Pharma AG, Basel, Switzerland; 3Department of Medicine, University of Leipzig, Leipzig, Germany Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0213897a5474b873fd4d6d243ba15331
https://doi.org/10.2147/ceor.s75935
https://doi.org/10.2147/ceor.s75935